A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Sofosbuvir Impurity 31 - Request Quote

Picture of Sofosbuvir Impurity 31

Sofosbuvir Impurity 31

SZ CAT No:SZ-S010054
CAS No
NA
Mol.F.
C24H23N3O7
Mol.Wt.
465.5
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Sofosbuvir Impurity 31 is chemically (2R,3R,4S,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-hydroxy-4-methyltetrahydrofuran-3-yl benzoate. Sofosbuvir Impurity 31 is supplied with detailed characterization data compliant with regulatory guideline. Sofosbuvir Impurity 31 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Sofosbuvir.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Sofosbuvir Impurity 31

Purchase Sofosbuvir Impurity 31

Sofosbuvir Impurity 31 suppliers

Sofosbuvir Impurity 31 manufacturers

Sofosbuvir Impurity 31 price

Order Sofosbuvir Impurity 31

Enquire Sofosbuvir Impurity 31

Sofosbuvir Impurity 31 cost

Sofosbuvir Impurity 31 Supplier

Sofosbuvir Impurity 31 Distributor

Sofosbuvir Impurity 31 for Method Validation

Sofosbuvir Reference Standard

Sofosbuvir Impurity 31 for ANDA Filing

Sofosbuvir Impurity 31 for Forced Degradation Studies

Sofosbuvir Impurity 31 Identification Standards

Sofosbuvir Impurity 31 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,